Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANABNASDAQ:COGTNASDAQ:RCKTNASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$20.44-1.4%$19.36$12.21▼$41.31$600.53M-0.2600,947 shs357,651 shsCOGTCogent Biosciences$4.82-2.6%$5.18$3.72▼$12.61$548.79M1.911.26 million shs877,172 shsRCKTRocket Pharmaceuticals$6.27-4.4%$6.72$4.55▼$26.98$669.55M1.021.51 million shs2.08 million shsTNGXTango Therapeutics$1.84-1.3%$1.46$1.03▼$12.02$199.45M1.021.26 million shs2.43 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-1.45%+1.09%+0.10%+9.79%-18.37%COGTCogent Biosciences-2.63%-1.23%+7.83%-39.75%-39.98%RCKTRocket Pharmaceuticals-4.42%-3.54%-12.18%-40.11%-72.06%TNGXTango Therapeutics-1.34%+22.67%+25.17%-22.03%-75.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANABAnaptysBio3.3326 of 5 stars4.43.00.00.03.21.70.6COGTCogent Biosciences2.3245 of 5 stars4.40.00.00.03.90.00.6RCKTRocket Pharmaceuticals4.9074 of 5 stars4.53.00.04.74.05.00.6TNGXTango Therapeutics1.8637 of 5 stars3.50.00.00.03.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.70Moderate Buy$35.8875.51% UpsideCOGTCogent Biosciences 2.75Moderate Buy$14.00190.46% UpsideRCKTRocket Pharmaceuticals 2.92Moderate Buy$37.73501.71% UpsideTNGXTango Therapeutics 3.00Buy$12.20563.04% UpsideCurrent Analyst Ratings BreakdownLatest TNGX, RCKT, ANAB, and COGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025COGTCogent BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.005/16/2025RCKTRocket PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$20.00 ➝ $30.005/16/2025RCKTRocket PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$32.00 ➝ $32.005/16/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $46.005/12/2025RCKTRocket PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $51.005/12/2025RCKTRocket PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $34.005/9/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$54.00 ➝ $45.005/9/2025RCKTRocket PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$45.00 ➝ $44.005/9/2025RCKTRocket PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/7/2025COGTCogent BiosciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$8.00 ➝ $7.005/6/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$111.87M5.37N/AN/A$3.32 per share6.16COGTCogent BiosciencesN/AN/AN/AN/A$2.30 per shareN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.46 per shareN/ATNGXTango Therapeutics$40.99M4.87N/AN/A$2.48 per share0.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$163.62M-$4.85N/AN/AN/A-289.75%-287.94%-37.25%8/4/2025 (Estimated)COGTCogent Biosciences-$192.41M-$1.84N/AN/AN/AN/A-112.55%-60.44%8/5/2025 (Estimated)RCKTRocket Pharmaceuticals-$245.60M-$2.63N/AN/AN/AN/A-62.62%-54.17%8/4/2025 (Estimated)TNGXTango Therapeutics-$101.74M-$1.22N/AN/AN/A-284.42%-49.64%-32.00%8/6/2025 (Estimated)Latest TNGX, RCKT, ANAB, and COGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025RCKTRocket Pharmaceuticals-$0.58-$0.56+$0.02N/AN/AN/A5/12/2025Q1 2025TNGXTango Therapeutics-$0.34-$0.36-$0.02-$0.36$6.73 million$5.39 million5/6/2025Q1 2025COGTCogent Biosciences-$0.56-$0.52+$0.04-$0.52N/AN/A5/5/2025Q1 2025ANABAnaptysBio-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 million5/5/2025Q1 2025RCKTRocket Pharmaceuticals-$0.59-$0.56+$0.03-$0.56$0.80 millionN/A3/3/2025Q4 2024RCKTRocket Pharmaceuticals-$0.68-$0.62+$0.06-$0.62$0.03 millionN/A2/27/2025Q4 2024ANABAnaptysBio-$1.61-$0.72+$0.89-$0.72$10.17 million$43.11 million2/27/2025Q4 2024TNGXTango Therapeutics-$0.32-$0.35-$0.03-$0.35$7.84 million$4.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A10.2310.23COGTCogent BiosciencesN/A6.446.44RCKTRocket Pharmaceuticals0.066.056.05TNGXTango TherapeuticsN/A8.008.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/ACOGTCogent BiosciencesN/ARCKTRocket Pharmaceuticals98.39%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%COGTCogent Biosciences5.92%RCKTRocket Pharmaceuticals24.76%TNGXTango Therapeutics6.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.38 million20.17 millionOptionableCOGTCogent Biosciences80113.86 million103.92 millionOptionableRCKTRocket Pharmaceuticals240106.79 million65.18 millionOptionableTNGXTango Therapeutics90108.39 million100.65 millionOptionableTNGX, RCKT, ANAB, and COGT HeadlinesRecent News About These CompaniesTango Therapeutics starts trial for brain cancer drugMay 23 at 11:17 AM | uk.investing.comTango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid TumorsMay 21 at 7:00 AM | globenewswire.com517,426 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Jacobs Levy Equity Management Inc.May 19, 2025 | marketbeat.comQ2 EPS Estimate for Tango Therapeutics Increased by AnalystMay 17, 2025 | marketbeat.comDimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)May 17, 2025 | marketbeat.comLeerink Partnrs Brokers Boost Earnings Estimates for TNGXMay 17, 2025 | americanbankingnews.comTango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target PriceMay 16, 2025 | finance.yahoo.comOrbimed Advisors LLC Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)May 15, 2025 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Posts Earnings Results, Misses Estimates By $0.02 EPSMay 14, 2025 | marketbeat.comAnalyzing Tango Therapeutics (NASDAQ:TNGX) and Rosetta Genomics (OTCMKTS:ROSGQ)May 14, 2025 | americanbankingnews.comTango Therapeutics Reports Q1 2025 Financial Results and Updates on TNG462 and Pipeline DevelopmentsMay 14, 2025 | nasdaq.comTango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 13, 2025 | finanznachrichten.deTango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 13, 2025 | finance.yahoo.comTango Therapeutics Extends Cash Runway Amid Clinical ProgressMay 13, 2025 | tipranks.comTango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue EstimatesMay 12, 2025 | zacks.comTango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 12, 2025 | globenewswire.com4,000,000 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Bought by Farallon Capital Management LLCMay 11, 2025 | marketbeat.comBalyasny Asset Management L.P. Has $10.13 Million Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)May 11, 2025 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Buy" by AnalystsMay 11, 2025 | marketbeat.comTango Therapeutics (TNGX) to Release Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comTango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseMay 5, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNGX, RCKT, ANAB, and COGT Company DescriptionsAnaptysBio NASDAQ:ANAB$20.44 -0.30 (-1.45%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$20.40 -0.04 (-0.20%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Cogent Biosciences NASDAQ:COGT$4.82 -0.13 (-2.63%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.94 +0.12 (+2.57%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Rocket Pharmaceuticals NASDAQ:RCKT$6.27 -0.29 (-4.42%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$6.28 +0.01 (+0.08%) As of 05/23/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Tango Therapeutics NASDAQ:TNGX$1.84 -0.03 (-1.34%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.86 +0.02 (+1.36%) As of 05/23/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
